James Yu
Research Subjects
Research Interests
James Yu has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Ayako Ishii
CellMark Japan, Tokyo 102-0071, Japan
1 shared publication - Kate Hsu
Contek Life Science Co., Ltd., Taipei City 100007, Taiwan
1 shared publication - Masashi Kitamura
Faculty of Pharmacy and Pharmaceutical Sciences, Josai University, Sakado-shi, Japan
1 shared publication - Ryuichiro Suzuki
Faculty of Pharmacy and Pharmaceutical Sciences, Josai University, Sakado, Japan
1 shared publication - Shinder Chen
Contek Life Science Co., Ltd., Taipei City 100007, Taiwan
1 shared publication - Takami Yokogawa
School of Pharmacy Josai University Saitama Japan
1 shared publication
Latest Publications
- Open Access
Degradative Effect of Nattokinase on Spike Protein of SARS-CoV-2
The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged as a pandemic and has inflicted enormous damage on the lives of the people and economy of many countries worldwide. However, therapeutic agents against SARS-CoV-2 remain unclear. SARS-CoV-2 has a spike protein (S protein), and cleavage of the S protein is essential for viral entry. Nattokinase is produced by Bacillus subtilis var. natto and is beneficial to human health. In this study, we examined the effect of nattokinase on the S protein of SARS-CoV-2. When cell lysates transfected with S protein were incubated with nattokinase, the S protein was degraded in a dose- and time-dependent manner. Immunofluorescence analysis showed that S protein on the cell surface was degraded when nattokinase was added to the culture medium. Thus, our findings suggest that nattokinase exhibits potential for the inhibition of SARS-CoV-2 infection via S protein degradation.
Open AccessDegradative Effect of Nattokinase on Spike Protein of SARS-CoV-2
The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged as a pandemic and has inflicted enormous damage on the lives of the people and economy of many countries worldwide. However, therapeutic agents against SARS-CoV-2 remain unclear. SARS-CoV-2 has a spike protein (S protein), and cleavage of the S protein is essential for viral entry. Nattokinase is produced by Bacillus subtilis var. natto and is beneficial to human health. In this study, we examined the effect of nattokinase on the S protein of SARS-CoV-2. When cell lysates transfected with S protein were incubated with nattokinase, the S protein was degraded in a dose- and time-dependent manner. Immunofluorescence analysis showed that S protein on the cell surface was degraded when nattokinase was added to the culture medium. Thus, our findings suggest that nattokinase exhibits potential for the inhibition of SARS-CoV-2 infection via S protein degradation.